Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus

Emil Wolsk; Brian Claggett; Rafael Diaz; Kenneth Dickstein; Hertzel C Gerstein; Lars Køber; Francesca C Lawson; Eldrin F Lewis; Aldo P Maggioni; John J V McMurray; Jeffrey L Probstfield; Matthew C Riddle; Scott D Solomon; Jean-Claude Tardif; Marc A Pfeffer

doi:10.1161/CIRCULATIONAHA.117.029503

Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus

Circulation. 2017 Oct 17;136(16):1560-1562. doi: 10.1161/CIRCULATIONAHA.117.029503.

Authors

Affiliations

¹ From Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (E.W., B.C., E.F.L., S.D.S., M.A.P.); Department of Cardiology, Rigshospitalet, Copenhagen, Denmark (E.W., L.K.); Estudios Clínicos Latinoamérica, Rosario, Argentina (R.D.); University of Bergen, Stavanger University Hospital, Norway (K.D.); Division of Endocrinology & Metabolism, McMaster University, Hamilton, Ontario, Canada (H.C.G.); Sanofi US, Bridgewater, NJ (F.C.L.); Research Center of the Italian Association of Hospital Cardiologists, Florence, Italy (A.P.M.); British Heart Foundation Cardiovascular Research Centre, University of Glasgow, United Kingdom (J.J.V.M.); Division of Cardiology, University of Washington Medical Center, Seattle (J.L.P.); Division of Endocrinology, Oregon Health and Science University, Portland (M.C.R.); and Montreal Heart Institute, Université de Montréal, Quebec, Canada (J.-C.T.).
² From Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (E.W., B.C., E.F.L., S.D.S., M.A.P.); Department of Cardiology, Rigshospitalet, Copenhagen, Denmark (E.W., L.K.); Estudios Clínicos Latinoamérica, Rosario, Argentina (R.D.); University of Bergen, Stavanger University Hospital, Norway (K.D.); Division of Endocrinology & Metabolism, McMaster University, Hamilton, Ontario, Canada (H.C.G.); Sanofi US, Bridgewater, NJ (F.C.L.); Research Center of the Italian Association of Hospital Cardiologists, Florence, Italy (A.P.M.); British Heart Foundation Cardiovascular Research Centre, University of Glasgow, United Kingdom (J.J.V.M.); Division of Cardiology, University of Washington Medical Center, Seattle (J.L.P.); Division of Endocrinology, Oregon Health and Science University, Portland (M.C.R.); and Montreal Heart Institute, Université de Montréal, Quebec, Canada (J.-C.T.). [email protected].

PMID: 29038210
DOI: 10.1161/CIRCULATIONAHA.117.029503

No abstract available

Keywords: heart failure; natriuretic peptides.

Publication types

Letter

MeSH terms

Acute Coronary Syndrome / blood*
Acute Coronary Syndrome / diagnosis
Acute Coronary Syndrome / therapy
Aged
Biomarkers / blood
Diabetes Mellitus, Type 2 / blood*
Diabetes Mellitus, Type 2 / diagnosis
Diabetes Mellitus, Type 2 / drug therapy
Female
Heart Failure / blood*
Heart Failure / diagnosis
Heart Failure / therapy
Hospitalization*
Humans
Hypoglycemic Agents / therapeutic use
Male
Middle Aged
Natriuretic Peptide, Brain / blood*
Peptide Fragments / blood*
Peptides / therapeutic use
Randomized Controlled Trials as Topic
Risk Assessment
Risk Factors
Time Factors
Treatment Outcome
Up-Regulation

Substances

Biomarkers
Hypoglycemic Agents
Peptide Fragments
Peptides
pro-brain natriuretic peptide (1-76)
Natriuretic Peptide, Brain
lixisenatide